Freedom Investment Management Inc. Sells 228 Shares of DaVita Inc. (NYSE:DVA)

Freedom Investment Management Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 11.7% during the third quarter, HoldingsChannel.com reports. The firm owned 1,728 shares of the company’s stock after selling 228 shares during the quarter. Freedom Investment Management Inc.’s holdings in DaVita were worth $283,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in DVA. Transcendent Capital Group LLC bought a new stake in shares of DaVita in the 3rd quarter worth approximately $25,000. Blue Trust Inc. raised its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. purchased a new position in DaVita in the 2nd quarter worth approximately $43,000. Versant Capital Management Inc raised its holdings in DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares during the last quarter. Finally, Friedenthal Financial purchased a new position in DaVita in the 2nd quarter worth approximately $48,000. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of DVA opened at $166.17 on Monday. The firm has a market cap of $13.63 billion, a PE ratio of 17.93, a P/E/G ratio of 0.94 and a beta of 0.89. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a fifty day simple moving average of $158.57 and a two-hundred day simple moving average of $149.39. DaVita Inc. has a 1-year low of $99.18 and a 1-year high of $169.51.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the company earned $2.85 earnings per share. On average, equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on DVA shares. UBS Group boosted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $161.80.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.00% of the stock is currently owned by company insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.